22nd Century Group Inc. (NASDAQ: XXII) has appointed James A Mish to its Board. Currently, Mish is the company’s CEO, and the appointment significantly enriches the...
22nd Century Group Inc (NASDAQ: XXII) announced that it is granted Food and Drug Administration (FDA) approval to market and sell its VLN® King and VLN®...
22nd Century Group Inc. (NASDAQ: XXII) has announced Q3 2021 financial results and offered its recent business highlights. Net sales increased 6.9% In Q3 2021, net...
22nd Century Group Inc. (NYSEAMERICAN:XXII) has announced that it has received $8.1 million in net proceeds from the cash exercise of outstanding warrants. Notably, the remaining...
The year 2018 is a great period for 22nd Century Group Inc (NYSEAMERICAN:XXII). The plant biotechnology company is making great strides in reducing the tobacco harm...
Plant biotechnology firm 22nd Century Group Inc (NYSEAMERICAN:XXII) has revealed some updates on the Food and Drug Administration’s (FDA) plans to reduce nicotine levels to non-addictive...
22nd Century Group Inc (NYSEAMERICAN:XXII) has announced the receipt of responses to the nicotine reduction plan of US FDA. These submissions to the FDA is authored...
It was today that 22nd Century Group Inc (NYSEAMERICAN:XXII) disclosed that it had plans underway to expand its proprietary lines of VLN™ .By exclusively licensing from North...
Anytime from now FTSE Russell (Russell) will reconstitute its equity indexes, an undertaking that will have 22nd Century Group Inc (NYSEAMERICAN:XXII) added to the Russell 2000, Russell...
